Hiệu quả điều trị ung thư vòm hầu giai đoạn I-II bằng xạ trị ngoài kết hợp xạ trị áp sát=Treatment outcomes of EBRT combined with ICBT in early-stage nasopharyngeal cancer patients

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Huy Quốc Thịnh Đặng, Đức Hoàng Lâm, Kỷ Cương Nguyễn, Thị Bích Hiền Nguyễn, Thị Kim Ngân Nguyễn

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.35-43

Bộ sưu tập: Báo, Tạp chí

ID: 478108

Thêm vào giỏ

Đánh giá đáp ứng sau điều trị, độc tính cấp và độc tính muộn và xác định tỉ lệ kiểm soát tại chỗ tại vùng, sống còn không bệnh và sống còn toàn bộ ở bệnh nhân ung thư vòm hầu gia đoạn I-II. Đối tượng và phương pháp nghiên cứu: Nghiên cứu hồi cứu mô tả loạt ca bệnh trên bệnh nhân ung thư vòm hầu giai đoạn I-II tại BV Ung Bướu TPHCM từ 2014 – 2021. Kết quả: 107 bệnh nhân được lựa chọn vào nghiên cứu. Tỉ lệ nam/nữ là 3:2. Tuổi thường gặp từ 40 đến 60. Đa số (83%) bệnh nhân được xạ trị ngoài 3D-CRT và 17% xạ trị IMRT/VMAT. 50% bệnh nhân XTAS trong hốc cách tuần, còn lại nhận 12 – 20 Gy/ 3-4 Gy x 2 PL/ ngày. Đáp ứng tại chỗ đạt 100%. Độc tính cấp phổ biến nhất là viêm niêm mạc, viêm da
khô miệng và viêm niêm mạc mạn là độc tính muộn phổ biến nhất, chiếm 56% và 37,4% trường hợp. Tỉ lệ kiểm soát tại chỗ 2 năm 97,7%
DFS 2 năm và 5 năm là 96,8% và 92,1%. OS 2 năm, 5 năm tương ứng là 99% và 95%.dung nạp được. LRC, DFS và OS rất cao đến 92 – 99%.To evaluate the treatment response, investigate early and late toxicities, and to assess the local regional control (LRC) rate, disease-free survival (DFS) and overall survival (OS) of patients with stage I and II NPC Method: A retrospective case series collecting all early-stage NPC patients in HCMC oncology hospital treated by EBRT + ICBT from 2014 to 2021. Results: 107 patients were enrolled. The male: female ratio was 3:2. The common age ranged from 40 to 60. Most cases (83%) received EBRT with 3D-CRT, and 17% cases were treated with IMRT/VMAT. Weekly intracavity brachytherapy protocol treated 50% of patients, and the rest received a total of 12 – 20 Gy at 3 - 4 Gy/fraction twice daily. The local response rate was 100%. The most common early toxicities were mucositis, dermatitis
while the most common late toxicities were xerostomia and chronic mucositis, accounting for 56 % and 37.4%
respectively. The 2-yr LRC was 97.7%. The 2-yr and 5-yr DFS were 96.8% and 92.1%
OS were 99% and 95%, respectively. Conclusion: EBRT combined with ICBT is a safe treatment modality, with tolerable early and late toxicities. LRC, DFS and OS were high, 92 - 99%.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR